Immunodeficiency News and Research

RSS

Immunodeficiency (or immune deficiency) is a state in which the immune system's ability to fight infectious disease is compromised or entirely absent.

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.

From Baxter International Inc. 9 Jan 2012

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences, Inc. announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS.

9 Jan 2012

New HIV vaccine candidates show promise in monkeys

"The quest for a vaccine against AIDS is gaining momentum, with research published Wednesday identifying promising new candidates that protected monkeys against a powerful strain of the virus and that soon could be tested in humans," the Wall Street Journal reports.

6 Jan 2012

Novel vaccine combinations can protect against infection by SIV

Results from a recent study show that novel vaccine combinations can provide partial protection against infection by Simian Immunodeficiency Virus (SIV) in rhesus monkeys.

5 Jan 2012

Study reveals factors associated with prevention, control of HIV infection

New vaccine research in monkeys suggests that scientists are homing in on the critical ingredients of a protective HIV vaccine and identifies new HIV vaccine candidates to test in human clinical trials.

5 Jan 2012

Viewpoints: Sebelius on 'essential benefits'; WSJ columnist on Democrats' 'Mediscare' argument - is it a lie?

Insurance needs and health systems vary state to state, and experience tells us that the best way forward is not to mandate a one-size-fits-all answer. Instead, our approach gives states the flexibility to take their own paths, while ensuring they all end up in the best place possible: with an Affordable Insurance Exchange that offers access to comprehensive, quality, affordable health insurance to small business owners and individuals who currently have few good choices in an expensive and broken market.

5 Jan 2012

UC Davis professor monitors world's hot spots for signs of emerging diseases

It's not a matter of if a worldwide pandemic will strike but when, say experts like veterinarian and epidemiologist Jonna Mazet, a professor in the Department of Medicine and Epidemiology in the University of California, Davis, School of Veterinary Medicine. That's why Mazet, who leads an early warning pandemic system called PREDICT, monitors the world's hot spots, or "hot interfaces" for signs of emerging diseases.

21 Dec 2011

Aethlon Hemopurifier can capture Nef protein exosomes linked with HIV

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome.

14 Dec 2011

Obama pledges more for fighting HIV/AIDS

On the occasion of World AIDS day on 1st December, President Barack Obama vowed to boost U.S. efforts to fight AIDS with a new target of providing treatment to 6 million people worldwide by 2013, up from an earlier goal of 4 million.

4 Dec 2011

Research roundup: Recession's big impact on men's insurance coverage

Researchers examined three sets of surveillance data and found that of the estimated 1.2 million persons in the United States living with the human immunodeficiency virus, 942,000 persons were aware of their infection. More than three-quarters of those were "linked to care" and among HIV-infected adults in care, "45 percent received prevention counseling, and 89 percent were prescribed antiretroviral therapy."

3 Dec 2011

On World AIDS Day, Obama announces plan to redirect $50 million to fight AIDS

President Barack Obama told advocates, patients and other stakeholders that his administration will do more to get antiretroviral drugs to people infected with HIV -; in the United States and in low-income countries around the world.

3 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011

Global leaders plan next steps at Harvard on World AIDS Day

Thirty years, 30 million deaths and 60 million infections after HIV appeared, medical researchers now have the tools to halt the deadly epidemic. "We have the weapons to win the war against AIDS," says Richard Marlink, M.D., Executive Director of the AIDS Initiative at the Harvard School of Public Health. "It is time to take what we have learned to turn the epidemic around and end AIDS."

30 Nov 2011

Annual report on sexually transmitted infections reveals rising trends

New figures reveal that cases of some common sexually spread diseases continue to increase in the United States. These numbers come in the annual report on sexually transmitted disease released by health officials this Thursday.

17 Nov 2011

FDA licenses NYBC's HEMACORD stem cell product

The Food and Drug Administration has licensed HEMACORD for allogeneic hematopoietic (blood-forming) stem cell transplantation, the first such approval of a stem cell product in the world.

11 Nov 2011

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

8 Nov 2011

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

Baxter International Inc. today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI).

From Baxter International Inc. 7 Nov 2011

Study provides blueprint for design of new HIV drugs

Scientists have moved a step closer to understanding how one of our body's own proteins helps stop the human immunodeficiency virus (HIV-1) in its tracks.

7 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011

HIV and AIDS do not discriminate

They don't discriminate. They can affect the young, older adults and pregnant women. They also strike rich and poor, male and female. People from all walks of life can become infected with HIV and AIDS. Knowing how to prevent them, how to live with them, and the strides made over the years to fight them are essential. This knowledge is one of the main goals of World AIDS Day, which is observed on December 1 each year.

5 Nov 2011